UK markets closed
  • FTSE 100

    -168.53 (-2.53%)
  • FTSE 250

    -287.75 (-1.36%)
  • AIM

    -8.61 (-0.72%)

    +0.0039 (+0.34%)

    -0.0091 (-0.65%)

    +612.17 (+1.84%)
  • CMC Crypto 200

    -20.25 (-2.17%)
  • S&P 500

    -18.19 (-0.48%)
  • DOW

    -469.64 (-1.50%)

    -1.87 (-2.94%)

    -42.40 (-2.39%)
  • NIKKEI 225

    -1,202.26 (-3.99%)

    -1,093.96 (-3.64%)
  • DAX

    -93.04 (-0.67%)
  • CAC 40

    -80.67 (-1.39%)

Global Stem Cell Partnering Terms and Agreements Directory 2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target & Technology Type

Research and Markets
·4-min read

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to's offering.

The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

Report scope

Stem Cell Partnering Terms and Agreements includes:

  • Trends in Stem Cell dealmaking in the biopharma industry since 2010

  • Analysis of Stem Cell deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life Stem Cell deals

  • Access to Stem Cell contract documents

  • Leading Stem Cell deals by value since 2010

  • Most active Stem Cell dealmakers since 2010

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking
2.1. Introduction
2.2. Stem Cell partnering over the years
2.3. Most active Stem Cell dealmakers
2.4. Stem Cell partnering by deal type
2.5. Stem Cell partnering by therapy area
2.6. Deal terms for Stem Cell partnering
2.6.1 Stem Cell partnering headline values
2.6.2 Stem Cell deal upfront payments
2.6.3 Stem Cell deal milestone payments
2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals
3.1. Introduction
3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers
4.1. Introduction
4.2. Most active Stem Cell dealmakers
4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory
5.1. Introduction
5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking


  • Appendix 1 - Stem Cell deals by company A-Z

  • Appendix 2 - Stem Cell deals by stage of development

  • Appendix 3 - Stem Cell deals by deal type

  • Appendix 4 - Stem Cell deals by therapy area

  • Appendix 5 -Deal type definitions

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900